CN116850247A - 一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 - Google Patents
一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 Download PDFInfo
- Publication number
- CN116850247A CN116850247A CN202311019025.1A CN202311019025A CN116850247A CN 116850247 A CN116850247 A CN 116850247A CN 202311019025 A CN202311019025 A CN 202311019025A CN 116850247 A CN116850247 A CN 116850247A
- Authority
- CN
- China
- Prior art keywords
- parts
- gout
- hyperuricemia
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 201000005569 Gout Diseases 0.000 title claims abstract description 45
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000284 extract Substances 0.000 claims abstract description 15
- 239000004863 Frankincense Substances 0.000 claims abstract description 13
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 9
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 9
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 9
- 239000000341 volatile oil Substances 0.000 claims abstract description 9
- 241000758794 Asarum Species 0.000 claims abstract description 8
- 235000003717 Boswellia sacra Nutrition 0.000 claims abstract description 8
- 240000007551 Boswellia serrata Species 0.000 claims abstract description 8
- 235000012035 Boswellia serrata Nutrition 0.000 claims abstract description 8
- 238000001816 cooling Methods 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 7
- 244000144730 Amygdalus persica Species 0.000 claims description 6
- 244000020518 Carthamus tinctorius Species 0.000 claims description 6
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 6
- 241000361919 Metaphire sieboldi Species 0.000 claims description 6
- 244000197580 Poria cocos Species 0.000 claims description 6
- 235000008599 Poria cocos Nutrition 0.000 claims description 6
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 6
- 240000007164 Salvia officinalis Species 0.000 claims description 6
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 241000717739 Boswellia sacra Species 0.000 claims description 5
- 229920000858 Cyclodextrin Polymers 0.000 claims description 5
- 239000001116 FEMA 4028 Substances 0.000 claims description 5
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
- 229960004853 betadex Drugs 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 235000017276 Salvia Nutrition 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 235000021419 vinegar Nutrition 0.000 claims description 3
- 239000000052 vinegar Substances 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 235000005412 red sage Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 240000001949 Taraxacum officinale Species 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 229940079593 drug Drugs 0.000 abstract description 27
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 230000000740 bleeding effect Effects 0.000 abstract description 5
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 231100000171 higher toxicity Toxicity 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 27
- 229940116269 uric acid Drugs 0.000 description 27
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 16
- 239000008187 granular material Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 230000001603 reducing effect Effects 0.000 description 9
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000286209 Phasianidae Species 0.000 description 4
- 241000245665 Taraxacum Species 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000008087 TBil Methods 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 244000137773 Viola philippica Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明所提供的一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,通过先将乳香、没药、细辛以及黑顺片四味药,进行水蒸气提取,分别得到挥发油和水相提取物,最后再将剩余的十二味药材进行水提取,合并提取物后,所得的提取物改善了毒性较大的问题,且保留了原有的药效,有清热解毒、消肿排脓、凉血止血的功效,对高尿酸血症与痛风患者更具有针对性,增强了受损关节处的消肿抗炎,具有标本兼治、疗效显著、副作用小、服用方便、价格经济等优点,生产工艺简单高效,利于工业化生产。
Description
技术领域
本发明中药技术领域,具体涉及一种治疗高尿酸血和痛风的中药组合物制备方法及组合物。
背景技术
高尿酸血症,是尿酸合成增加和(或)尿酸排泄减少引起的一种代谢性疾病,不仅是急性关节炎、痛风石、肾结石和尿酸性肾病最主要的生化基础,而且与多种传统心血管疾病的危险因素如高龄、男性、肥胖、脂代谢紊乱、酗酒等并存,并与多种心血管疾病,如脑卒中、冠心病、痛风、糖尿病、心功能衰竭、慢性肾脏疾病等密切相关,严重威胁人类的健康。
痛风,是由于长期高尿酸血症导致尿酸盐沉淀于关节和软组织而形成的一组异质性、代谢类疾病。痛风的临床表现为反复发作的急性关节炎、痛风石沉淀、痛风性慢性关节炎和关节畸形,常累及肾脏,易引起慢性间质性肾炎、肾结石等。
目前针对痛风的治疗主要以西药为主,包括秋水仙碱、别嘌呤醇、非布司他、苯溴马隆等。其中,秋水仙碱是治疗痛风急性发作的首选药,能显著缓解痛风引起的症状,但80%的患者在治疗剂量下会出现恶心、腹泻、呕吐、肠胃不适等症状,停药后易出现“反跳”,不宜长期使用;别嘌呤醇和非布司他是通过抑制XO,阻断次黄嘌呤向黄嘌呤的尿酸转化的原理,降低血尿酸浓度,抑制痛风的,使用后可能会引起不同程度的肝肾损伤及不良反应,如肾功能衰竭、史蒂文斯-约尔逊综合征等;苯溴马隆是一种促尿酸排泄类药物,其作用机制主要是抑制尿酸盐在近曲小管的主动再吸收,增加尿酸盐的排泄而降低血中尿酸浓度,促进尿酸盐溶解;苯溴马隆,曾被认为是最有潜力的促尿酸排泄剂,但由于具有潜在的肝毒性而被欧洲一些国家限制使用,而在国内仍作为促尿酸排泄的主要药物在临床广泛使用。
发明人在研究中发现,常规的中药进行水提的过程中,即水煮,过滤,离心,提取,然后干燥粉碎,会产生一定的毒性,这种毒性在动物实验的过程中出现动物死亡的现象。
因此,亟需研制一种不具有毒性的治疗高尿酸血和痛风的中药组合物制备方法及组合物。
发明内容
本发明提供一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,可达到清热养阴、活血祛湿、化痰降浊、活血化瘀的功效,制备所得的中药组合物既改善了毒性又保留了药效。
为实现上述目的,本发明采用的技术方案是:
一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,包括以下步骤:
S1、按重量份称量乳香、没药、细辛以及黑顺片,加入10倍量水,水蒸气蒸馏提取7-10h,得一次水相提取液和挥发油,将挥发油使用β-环糊精包结,冷藏过滤,低温干燥,粉碎,得包结物;
S2、将步骤S1中所得的一次水相提取液过滤浓缩,冷却至室温后离心,得离心液;
S3、按重量份数称取丹参、蒲公英、紫花地丁、茯苓、独活、土茯苓、桃仁、红花、鸡血藤、赤芍、川牛膝及地龙,加入10倍量水煎煮2-3次,合并每次煎煮后的煎液,过滤,将滤液与步骤S2中的离心液合并,浓缩得浸膏,减压干燥,粉碎,加入步骤S1中所得的包结物,混匀制粒,干燥即得。
优选的,步骤S2中,所述滤液浓缩至相对密度为1.00~1.05。
优选的,步骤S3中,所述滤液和离心液混匀后浓缩至相对密度为1.25~1.30。
优选的,所述步骤S3中加入步骤S1中所得的包结物,还包括甜味剂和β-环糊精。
优选的,步骤S1中,粉碎的目数为150-400目;步骤S3中,粉碎的目数为150-400目。
优选的,所述乳香为醋制乳香。
优选的,所述桃仁为燀桃仁。
一种如上任一项所述的制备方法制备所得的高尿酸血症和/或痛风的中药组合物,按重量份计,由以下组分组成:丹参10-20份、蒲公英10-20份、紫花地丁7-17份、茯苓10-20份、独活5-15份、土茯苓10-20份、燀桃仁10-20份、红花10-20份、鸡血藤5-15份、醋乳香10-20份、没药10-20份、赤芍10-20份、黑顺片10-20份、细辛7-17份、川牛膝10-20份、地龙5-15份。
上述发明所获得的配方其药理作用为:
丹参:具有活血化瘀、祛瘀止血、舒经通络之功效;蒲公英:具有利尿排毒、平抑肝阳、消炎抗菌之功效,该两味药为君药,能使周身之气通而不滞;
紫花地丁:具有清热解毒、凉血止血之功效;茯苓:具有利水渗湿、健脾和胃、养心安神之功效;独活:具有祛风除湿、通痹止痛、解表之功效;土茯苓:具有清热解毒、除湿、通利关节之功效,该四味药为臣药,可清热解毒,具有辅助君药起治疗作用;
燀桃仁:具有活血祛瘀,缓解气血淤滞引起的痛症和不适之功效;红花:具有活血通经、散瘀止痛之功效;鸡血藤:具有补血行血,通经活络之功效;醋乳香:具有活血止痛、通经之功效;没药:具有消肿生肌、理气止疼、活血祛瘀之功效;赤芍:具有清热凉血、化瘀止痛之功效;黑顺片:具有回阳救逆、补火助阳、散寒止痛之功效;细辛:具有解表散寒、祛风止痛、温肺化饮之功效,该八味药组合为佐药,可活血止痛,配合君药臣药治疗兼证;
川牛膝:具有活血祛瘀、通利关节、利尿通淋之功效;地龙:具有清热息风、通经活络、清肺平喘之功效,该两味药为使药,具有排除淤堵,清热通利,调和诸药的作用。
本申请具有以下优点:
1、本发明所提供的一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,通过先将乳香、没药、细辛以及黑顺片四味药,进行水蒸气提取,分别得到挥发油和水相提取物,最后再将剩余的十二味药材进行水提取,合并提取物后,所得的提取物改善了毒性较大的问题,且保留了原有的药效,有清热解毒、消肿排脓、凉血止血的功效,对高尿酸血症与痛风患者更具有针对性,增强了受损关节处的消肿抗炎,具有标本兼治、疗效显著、副作用小、服用方便、价格经济等优点,生产工艺简单高效,利于工业化生产。
2、本发明提供的一种治疗高尿酸血症和/或痛风的中药组合物具有很好的镇痛降尿酸作用,能改善患者关节疼痛、关节压痛、关节急性红肿和关节活动受限情况,疗效显著。
具体实施方式
下面结合实施例1-3对本发明的技术方案进行说明。
实施例1
一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,包括以下步骤:
S1、按重量份数称量乳香、没药、细辛以及黑顺片,加入10倍量水,水蒸气蒸馏提取7-10h,得一次水相提取液和挥发油,将挥发油使用β-环糊精包结,冷藏过滤,低温干燥,粉碎,得包结物;
S2、将步骤S1中所得的一次水相提取液过滤浓缩,冷却至室温后离心,得离心液;
S3、按重量份数称取丹参、蒲公英、紫花地丁、茯苓、独活、土茯苓、桃仁、红花、鸡血藤、赤芍、川牛膝及地龙,加入10倍量水煎煮2-3次,合并每次煎煮后的煎液,过滤,将滤液与步骤S2中的离心液合并,浓缩得浸膏,减压干燥,粉碎,加入步骤S1中所得的包结物,混匀制粒,干燥即得痛风颗粒膏粉。
临床测试方法:
(1)痛风颗粒膏粉对次黄嘌呤法高尿酸血症大鼠模型的药效实验
为表明本发明药物对高尿酸血症及痛风的治疗效果,采用实施例1制备的痛风颗粒膏粉对大鼠进行持续给药3天,并对次黄嘌呤(200mg/kg,ip)致高尿酸血症模型的大鼠血清尿酸水平的影响-注射次黄瞟吟,分别于给予造模药后0.5、1h取血测定血清尿酸。实验结果如下表1、表2、表3所示。
表1:痛风颗粒膏粉(给药3天,ig)对次黄嘌呤致高尿酸血症模型大鼠血清尿酸水平的影响-注射次黄嘌呤0.5小时后采血
表2:痛风颗粒膏粉(给药3天,ig)对次黄嘌呤致高尿酸血症模型大鼠血清尿酸水平的影响-注射次黄嘌呤1小时后采血
由表1和表2可得,低剂量与高剂量,两组均有统计学显著差异,P<0.01,当前试验方案经过重复验证,受试物降尿酸颗粒剂对次黄嘌呤诱导的尿酸升高有明显的抑制作用。
(2)痛风颗粒膏粉对酵母粉+腺嘌呤喂饲法诱导高尿酸血症大鼠模型药效实验
为表明本发明药物对高尿酸血症及痛风的治疗效果,采用含酵母粉和腺嘌呤饲料喂饲法建立高尿酸模型,并实施例1制备的痛风颗粒膏粉对大鼠进行持续给药28天,分别于给予给药13天、28天取血测定血清尿酸。实验结果如表3所示。
由表3可得,高剂量组在28天时具有有统计学显著差异,P<0.01,当前试验方案经过重复验证,受试物降尿酸颗粒剂对酵母粉+腺嘌呤喂饲法诱导的尿酸升高有明显的抑制作用。
(3)痛风颗粒膏粉对治疗鹌鹑高尿酸血症药效实验
为表明本发明药物对高尿酸血症及痛风的治疗效果,采用鹌鹑建立高尿酸模型(鹌鹑具有鸟类嘌呤代谢的基本特征,由于体内缺乏尿酸酶,尿酸是嘌呤代谢的最终产物,与人类的嘌呤代谢路径相似,所以能在较大程度上模拟人类的高尿酸血症),并实施例1制备的痛风颗粒膏粉对大鼠进行持续给药28天,分别于给予给药14天、28天取血测定血清尿酸。实验结果如表3所示。
表4:
实验期间,受试动物活动良好,无动物死亡,体重各组较为接近,从实验结果可以看出,给予受试药物28天后,各受试药物组出现血清尿酸水平显著下降,其中低剂量组降低幅度为16.7%、中剂量组15.1%、高剂量组28.1%、阳性药物组27.4%,其中高剂量组和阳性药物组较为接近,与模型对照组相比,两组均有统计学差异,P<0.05,当试前验方案经过重复验证,受试物降尿酸颗粒剂对鹌鹑高尿酸血症模型,具有降尿酸作用。
(5)痛风颗粒膏粉的长期毒性实验
为表明本发明药物在治疗高尿酸血症及痛风过程中的安全性,实施例1制备的痛风颗粒膏粉以15、30、60g/kg/天的剂量每天重复灌胃给予SD大鼠,连续给药28天,动物临床观察未见与药物相关的死亡及异常反应,体重、摄食量、体温、眼科检查、尿液检查、凝血功能指标均未见与给药相关的明显异常变化。各剂量组动物可见末次药后次日全部或部分红系相关指标和白细胞分类指标RBC、HGB、HCT降低,Retic(×1012/L,%)、Neut(×109/L,%)升高;各组部分动物可见末次药后次日粒细胞系统增生减低以及恢复期4周结束红细胞系统增生减低、形态无异常,其余未见明显异常。30、60g/kg/天/剂量组试验期间还可见TBil的升高,肝脏以及60g/kg/天/剂量组肾脏的脏器重量/脏体比/脏脑比等指标轻微增加。病理组织学检查各组分别有3/20、2/19、4/20、17/20的动物可见脾脏红髓髓外造血,0/10、0/10、6/10、8/10的雌性动物可见肝脏小叶中央肝细胞肥大;停药4周后病变均可恢复。实验期间,受试动物活动良好,无动物死亡,体重各组较为接近,从实验结果可以看出,各受试药物组出现血清尿酸水平显著下降,其中低剂量组降低幅度为16.7%、中剂量组15.1%、高剂量组28.1%、阳性药物组27.4%,其中高剂量组和阳性药物组较为接近,与模型对照组相比,两组均有统计学差异,P<0.05,当试前验方案经过重复验证,受试物降尿酸颗粒剂对鹌鹑高尿酸血症模型,有一定的降尿酸作用。
本发明所提供的一种治疗高尿酸血症和/或痛风的中药组合物的制备方法,通过先将乳香、没药、赤芍以及黑顺片四味药,进行水蒸气提取,分别得到挥发油和水相提取物,最后再将剩余的十二味药材进行水提取,合并提取物后,所得的提取物改善了毒性较大的问题,且保留了原有的药效,有清热解毒、消肿排脓、凉血止血的功效,对高尿酸血症与痛风患者更具有针对性,增强了受损关节处的消肿抗炎,具有标本兼治、疗效显著、副作用小、服用方便、价格经济等优点,生产工艺简单高效,利于工业化生产。
以上所述仅为本申请的较佳实施例而已,并不用以限制本申请,凡在本申请的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本申请的保护范围之内。
Claims (8)
1.一种治疗高尿酸血症和痛风的中药组合物的制备方法,其特征在于,包括以下步骤:
S1、按重量份称量乳香、没药、细辛以及黑顺片,加入10倍量水,水蒸气蒸馏提取7-10h,得一次水相提取液和挥发油,将挥发油使用β-环糊精包结,冷藏过滤,低温干燥,粉碎,得包结物;
S2、将步骤S1中所得的一次水相提取液过滤浓缩,冷却至室温后离心,得离心液;
S3、按重量份数称取丹参、蒲公英、紫花地丁、茯苓、独活、土茯苓、桃仁、红花、鸡血藤、赤芍、川牛膝及地龙,加入10倍量水煎煮2-3次,合并每次煎煮后的煎液,过滤,将滤液与步骤S2中的离心液合并,浓缩得浸膏,减压干燥,粉碎,加入步骤S1中所得的包结物,混匀制粒,干燥即得。
2.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:步骤S2中,所述滤液浓缩至相对密度为1.00~1.05。
3.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:步骤S3中,所述滤液和离心液混匀后浓缩至相对密度为1.25~1.30。
4.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:所述步骤S3中加入步骤S1中所得的包结物,还包括甜味剂和β-环糊精。
5.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:步骤S1中,粉碎的目数为150-400目;步骤S3中,粉碎的目数为150-400目。
6.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:所述乳香为醋制乳香。
7.根据权利要求1所述的高尿酸血症和痛风的中药组合物的制备方法,其特征在于:所述桃仁为燀桃仁。
8.一种如权利要求1-7任一项所述的制备方法制备所得的高尿酸血症和痛风的中药组合物,其特征在于:按重量份计,由以下组分组成:丹参10-20份、蒲公英10-20份、紫花地丁7-17份、茯苓10-20份、独活5-15份、土茯苓10-20份、燀桃仁10-20份、红花10-20份、鸡血藤5-15份、醋乳香10-20份、没药10-20份、赤芍10-20份、黑顺片10-20份、细辛7-17份、川牛膝10-20份、地龙5-15份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311019025.1A CN116850247A (zh) | 2023-08-14 | 2023-08-14 | 一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311019025.1A CN116850247A (zh) | 2023-08-14 | 2023-08-14 | 一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116850247A true CN116850247A (zh) | 2023-10-10 |
Family
ID=88236198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311019025.1A Pending CN116850247A (zh) | 2023-08-14 | 2023-08-14 | 一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116850247A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843663A (zh) * | 2010-05-20 | 2010-09-29 | 培力(南宁)药业有限公司 | 一种比水重的挥发油提取包裹制备方法 |
CN102824593A (zh) * | 2012-09-20 | 2012-12-19 | 杨卫彬 | 治疗慢性肾功能衰竭的中成药 |
CN104784643A (zh) * | 2015-04-29 | 2015-07-22 | 赵汝君 | 一种治疗子宫肌瘤、卵巢囊肿和子宫内膜异位症的药物 |
CN104800606A (zh) * | 2015-04-29 | 2015-07-29 | 赵汝君 | 一种治疗帕金森氏综合症的中药组合物 |
CN105878862A (zh) * | 2014-12-10 | 2016-08-24 | 赵汝君 | 一种治疗痛风和高尿酸血症、强直性脊柱炎的中药组合物 |
-
2023
- 2023-08-14 CN CN202311019025.1A patent/CN116850247A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101843663A (zh) * | 2010-05-20 | 2010-09-29 | 培力(南宁)药业有限公司 | 一种比水重的挥发油提取包裹制备方法 |
CN102824593A (zh) * | 2012-09-20 | 2012-12-19 | 杨卫彬 | 治疗慢性肾功能衰竭的中成药 |
CN105878862A (zh) * | 2014-12-10 | 2016-08-24 | 赵汝君 | 一种治疗痛风和高尿酸血症、强直性脊柱炎的中药组合物 |
CN104784643A (zh) * | 2015-04-29 | 2015-07-22 | 赵汝君 | 一种治疗子宫肌瘤、卵巢囊肿和子宫内膜异位症的药物 |
CN104800606A (zh) * | 2015-04-29 | 2015-07-29 | 赵汝君 | 一种治疗帕金森氏综合症的中药组合物 |
Non-Patent Citations (1)
Title |
---|
朱红林: "中医辨证治疗痛风40例临床观察", 中医药导报, vol. 19, no. 10, 28 October 2013 (2013-10-28), pages 105 - 107 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109674958A (zh) | 一种具有降尿酸功效的中药组合物及其制备方法和应用 | |
CN103386022B (zh) | 一种治疗结核性胸膜炎的中药组合物 | |
CN111481638A (zh) | 一种治疗溃疡性结肠炎的中药灌肠制剂及其制备方法 | |
AU2020103082A4 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation for treating gout and preparation method thereof | |
WO2005074952A1 (fr) | Medicament chinois pour le traitement du syndrome du colon irritable ainsi que preparation de celui-ci | |
CN1173726C (zh) | 一种治疗恶性肿瘤病的药物及其制备方法 | |
CN110025705A (zh) | 一种治疗特应性皮炎的中药组合物及其制备方法和应用 | |
CN102293928A (zh) | 治疗高尿酸血症及痛风性关节炎的中药组合物及其制备方法与应用 | |
CN116850247A (zh) | 一种治疗高尿酸血和痛风的中药组合物制备方法及组合物 | |
CN108210651B (zh) | 一种用于治疗糖尿病肾病的天然药物组合物及其制备方法 | |
CN103386101B (zh) | 一种治疗非特异性膀胱炎的中药制剂及其制备方法 | |
CN108619427B (zh) | 一种预防治疗痛风性关节炎的祛痛降酸药茶 | |
CN106880654B (zh) | 竹节参提取物在制备治疗鼻炎药物中的应用及组合物 | |
KR101452394B1 (ko) | 급성 및 만성 기관지염의 치료용 약제의 제조에 있어서곤약 및 그 추출물의 용도 | |
CN110946950A (zh) | 一种治疗老年期血管性痴呆的中药组合物及其制备方法 | |
CN113521206B (zh) | 一种含有牛蒡子的中药组合物 | |
CN103933154A (zh) | 一种治疗痛风病的中药组合物及其制备方法 | |
CN117442677B (zh) | 一种用于肾损伤的药物组合物及其制备方法和用途 | |
CN115957274B (zh) | 一种治疗糖尿病的中药组合物、活血通络凝胶组合物和制备方法 | |
CN117462642B (zh) | 一种治疗腹泻的中药组合物及其制备方法和用途 | |
CN116808145B (zh) | 一种治疗慢性肾脏病的中药组合物 | |
CN114404433B (zh) | 一种改善微循环的松脂醇二葡萄糖苷组合物及其制备方法 | |
CN116832085B (zh) | 一种改善慢性肾功能衰竭患者临床症状的中药组合物 | |
CN107875269B (zh) | 一种治疗妇科炎症的中药组合物及其制备方法 | |
CN118078930A (zh) | 治疗高尿酸血症与其并发症的中药组合物及制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |